FIGURE 1.

Survival analysis of reaching EDSS ≥4.0 based on RoAD score ≥4 (dashed line) and <4 (solid line) by Cox regression analysis. (a)HR displayed, followed by 95% confidence intervals. Model fitness indicated by Omnibus χ2. (A) Unadjusted regression analysis on RoAD score without controlling for sex and immunotherapy groups. (B) Regression controlled for sex (HR 1.5, 0.7–3.1, p > 0.05) and immunotherapy groups (“EMA 1st line”: interferon beta, glatiramer acetate, dimethyl fumarate, and teriflunomide; “EMA 2nd line”: fingolimod, natalizumab, and ocrelizumab) and trajectory of follow‐up treatment changes. Immunotherapy (based on EMA 1st or 2nd line) and the trajectory of treatment changes during follow‐up did not significantly influence the outcome (HR 1.06 [0.3–3–8; p = 0.92] and HR 0.9 [0.5–1.7; p = 0.81]). Abbreviations: EMA: European Medical Agency, (a) HR: (adjusted) hazard ratio, RoAD score: risk of ambulatory disability score